£885.00

The 2026-2031 World Outlook for Drugs for Rheumatoid Arthritis

Subjects

Price data last checked 18 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£885 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 73 days · 73 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 73 days • 1 price levels

Days at Price

Price Analysis

Most common price: £885 (73 days, 100.0%)

Price range: £885 - £885

Price levels: 1 different prices over 73 days

Description

This study covers the world outlook for drugs for rheumatoid arthritis across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of drugs for rheumatoid arthritis as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Amgen, Biogen, Bristol-Myers Squibb, F. Hoffman-La Roche, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma, Pfizer, and UCB Biosciences. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2025).

Product Specifications

Format: paperback
ASIN: B0FHL3MTT4
Category: Books > Subjects
Domain: Amazon UK
Release Date: 04 June 2025
Listed Since: 15 July 2025

The 2026-2031 World Outlook for Drugs for Rheumatoid Arthritis

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2026-2031 World Outlook for Rheumatoid Arthritis Treatments

The 2025-2030 World Outlook for Rheumatoid Arthritis Treatments

The 2023-2028 Outlook for Rheumatoid Arthritis Treatments in China

The 2023-2028 Outlook for Rheumatoid Arthritis Treatments for US Zip Codes

The 2023-2028 Outlook for Psoriatic Arthritis Treatments in the United States

Rheumatoid Arthritis: Methods and Protocols: 2766 (Methods in Molecular Biology, 2766)

Rheumatoid Arthritis: Other Perspectives towards a Better Practice

IntechOpen Rheumatoid Arthritis - Etiology and Consequences

Insights and Perspectives in Rheumatology

Rheumatoid Arthritis - Treatment

The 2023-2028 Outlook for Psoriatic Arthritis Treatments in China

The 2025-2030 World Outlook for Psoriatic Arthritis Therapeutics

Innovative Rheumatology

Textbook of Rheumatology: v. 2

Rheumatoid Arthritis

Global Rheumatology, An Issue of Rheumatic Disease Clinics of North America (Volume 52-2) (The Clinics: Internal Medicine, Volume 52-2)

Challenges in Rheumatology

The 2026-2031 World Outlook for Anti-Inflammatory Lupus Drugs

Encyclopedia of Rheumatoid Arthritis

The Giants of Rheumatology, An Issue of Rheumatic Disease Clinics of North America: Volume 50-1 (The Clinics: Internal Medicine, Volume 50-1)

The 2023-2028 World Outlook for Osteoarthritis Treatments

Neyroimmunologicheskaya kharakteristika bol'nykh revmatoidnym artritom: Monografiya

Psychosomatik, Radiologie, Immunologie, Pathologie, Klinik und Therapie Rheumatischer Erkrankungen: Vorträge des Kongresses der Deutschen Gesellschaft für Rheumatologie Regensburg, 28. September bis 2. Oktober 1976

Treatment of Rheumatoid Arthritis